Identification

Name
Deferasirox
Accession Number
DB01609
Type
Small Molecule
Groups
Approved, Investigational
Description

Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.

Structure
Thumb
Synonyms
  • Deferasiroxum
  • ICL 670
  • ICL 670a
External IDs
ICL-670 / ICL-670A / ICL670 / ICL670A
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ExjadeTablet, film coated90 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension125 mgOralNovartis2006-11-10Not applicableCanada
ExjadeTablet, film coated360 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension500 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated180 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated90 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension125 mg/1OralNovartis2005-11-30Not applicableUs
ExjadeTablet, for suspension500 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-deferasiroxTablet, for suspension125 mgOralApotex Corporation2017-06-26Not applicableCanada
Apo-deferasiroxTablet, for suspension500 mgOralApotex Corporation2017-06-26Not applicableCanada
Apo-deferasiroxTablet, for suspension250 mgOralApotex Corporation2017-06-29Not applicableCanada
PMS-deferasiroxTablet, for suspension500 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-deferasiroxTablet, for suspension250 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-deferasiroxTablet, for suspension125 mgOralPharmascience IncNot applicableNot applicableCanada
Taro-deferasiroxTablet, for suspension500 mgOralTaro Pharmaceuticals, Inc.2017-06-30Not applicableCanada
Taro-deferasiroxTablet, for suspension250 mgOralTaro Pharmaceuticals, Inc.2017-06-26Not applicableCanada
Taro-deferasiroxTablet, for suspension125 mgOralTaro Pharmaceuticals, Inc.2017-06-26Not applicableCanada
Teva-deferasiroxTablet, for suspension125 mgOralTeva2017-06-26Not applicableCanada
International/Other Brands
Exjade
Categories
UNII
V8G4MOF2V9
CAS number
201530-41-8
Weight
Average: 373.3615
Monoisotopic: 373.106255983
Chemical Formula
C21H15N3O4
InChI Key
BOFQWVMAQOTZIW-UHFFFAOYSA-N
InChI
InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
IUPAC Name
4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
SMILES
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O

Pharmacology

Indication

For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions
Pharmacodynamics

Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.

Mechanism of action

Two molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.

TargetActionsOrganism
AIron
chelator
Human
Absorption

The absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.

Volume of distribution
  • 14.37 ± 2.69 L
Protein binding

Deferasirox is highly (~99%) protein bound almost exclusively to serum albumin.

Metabolism

Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.

Route of elimination

Deferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).

Half life

The mean elimination half-life ranged from 8 to 16 hours following oral administration.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Deferasirox.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Deferasirox.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Deferasirox.
AbciximabThe risk or severity of gastrointestinal bleeding can be increased when Abciximab is combined with Deferasirox.
AbemaciclibThe serum concentration of Abemaciclib can be decreased when it is combined with Deferasirox.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Deferasirox.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Deferasirox.
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Deferasirox.
AcenocoumarolThe risk or severity of gastrointestinal bleeding can be increased when Acenocoumarol is combined with Deferasirox.
Food Interactions
  • Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.
  • Food causes inconsistent increases in the bioavailability of this product.
  • Tablets should be completely dispersed in water, orange juice or apple juice and the resulting suspension should be ingested immediately (after swallowing the suspension, any residue should be resuspended in a small volume of liquid and swallowed).
  • Tablets should be taken on an empty stomach at least 30 minutes before a meal, preferably at the same time everyday.

References

Synthesis Reference

Rajendra Suryabhan Patil, Kishore Charugundla, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson, "SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF." U.S. Patent US20110171138, issued July 14, 2011.

US20110171138
General References
Not Available
External Links
Human Metabolome Database
HMDB0015547
KEGG Drug
D03669
PubChem Compound
5493381
PubChem Substance
46506791
ChemSpider
10770206
BindingDB
50088376
ChEBI
49005
ChEMBL
CHEMBL550348
PharmGKB
PA164760843
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Deferasirox
ATC Codes
V03AC03 — Deferasirox
AHFS Codes
  • 64:00.00 — Heavy Metal Antagonists

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentHigh Risk MDS or AML Patients1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHepatic Impairment1
1CompletedTreatmentTransfusional Iron Overload / Β-thalassemia1
1Not Yet RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Leukemia Acute Myeloid Leukemia (AML)1
1, 2Active Not RecruitingTreatmentSmith-Magenis Syndrome1
1, 2Active Not RecruitingTreatmentThalassemia Major With Severe Transfusional Iron Overload1
1, 2CompletedTreatmentAcute iron intoxication / Hereditary Haemochromatosis1
1, 2CompletedTreatmentIncreased Iron Storage / Disturbed Distribution / Non-Alcoholic Steatohepatitis1
1, 2Unknown StatusTreatmentThalassaemic disorders1
2Active Not RecruitingTreatmentTransfusion-dependent Anemia1
2CompletedSupportive CareAcute Undifferentiated Leukemia (AUL) / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Grade III Lymphomatoid Granulomatosis / Adult Langerhans Cell Histiocytosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Malignant mast cell neoplasm / Myelodysplastic Syndrome With Isolated Del(5q) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myeloid/NK-cell Acute Leukemia / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Anemia / Refractory Multiple Myeloma / Secondary Myelofibrosis / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Multiple Myeloma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Myeloid Leukemia / Waldenström's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Patients With Int 1-risk Myelodysplastic Syndrome / Adult Patients With Low Risk Myelodysplastic Syndrome / Adult Patients With Low- and Int-1-risk Myelodysplastic Syndrome1
2CompletedTreatmentAnemias / Hemosiderosis1
2CompletedTreatmentAplastic Anaemia (AA) / Beta-Thalassemia / Congenital Hypoplastic Anemia / Fanconi Syndrome / Myelodysplastic Syndromes1
2CompletedTreatmentBeta Thalassemia Transfusion Dependent1
2CompletedTreatmentAcute iron intoxication / Beta-Thalassemia1
2CompletedTreatmentCardiac Iron Overload1
2CompletedTreatmentCardiac Iron Overload / Transfusion-dependent β-thalassemia Patients1
2CompletedTreatmentChronic Anemia / Transfusional Hemosiderosis1
2CompletedTreatmentChronic Iron Overload Due to Transfusion-dependant Anemias1
2CompletedTreatmentAcute iron intoxication / Hemolytic Anemia / Sickle Cell Disorders1
2CompletedTreatmentMucormycosis1
2CompletedTreatmentMyelodysplastic Syndromes1
2CompletedTreatmentAcute iron intoxication / Myelodysplastic Syndromes1
2CompletedTreatmentAcute iron intoxication / Myelodysplastic Syndrome1
2CompletedTreatmentNon-transfusion Dependent Thalassemia1
2CompletedTreatmentPediatric Rare Anemia / Transfusional Iron Overload / Β-thalassemia Major1
2CompletedTreatmentSickle Cell Disorders2
2CompletedTreatmentTransfusional Hemosiderosis / Transfusional Iron Overload1
2CompletedTreatmentTransfusional Iron Overload2
2RecruitingTreatmentAnemias / Myelodysplastic Syndrome1
2RecruitingTreatmentHereditary Haemochromatosis1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentMyelodysplasia1
2RecruitingTreatmentPostmenopausal Osteoporosis (PMO)1
2RecruitingTreatmentThalassemia Major (TM)1
2TerminatedBasic ScienceMyelodysplastic Syndrome1
2TerminatedSupportive CareAccelerated Phase Chronic Myelogenous Leukemia / Acute iron intoxication / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Atypical Chronic Myeloid Leukemia, BCR-ABL Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Chronic Lymphocytic Leukemia (CLL) - Refractory / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / De Novo Myelodysplastic Syndromes / Disseminated Neuroblastoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Poor Prognosis Metastatic Gestational Trophoblastic Tumor / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Neuroblastoma / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Myelodysplastic Syndromes / Splenic Marginal Zone Lymphoma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage II Ovarian Epithelial Cancer / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Malignant Testicular Germ Cell Tumor / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Multiple Myeloma / Stage III Ovarian Epithelial Cancer / Stage III Small Lymphocytic Lymphoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Breast Cancer / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Ovarian Epithelial Cancer / Stage IV Small Lymphocytic Lymphoma1
2TerminatedSupportive CareAcute iron intoxication / Cancer of the Ovary / Cancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Neuroblastomas1
2TerminatedTreatmentHemochromatosis / Myelodysplastic Syndromes1
2TerminatedTreatmentHigh Risk MDS1
2TerminatedTreatmentMyelodysplastic Syndromes2
2Unknown StatusTreatmentPorphyria Cutanea Tarda1
2WithdrawnTreatmentAcute iron intoxication / Beta-Thalassemia / Iron Chelation / Iron Metabolism Disorders / Metabolic Diseases / Transfusional Hemosiderosis / Transfusional Iron Overload1
2WithdrawnTreatmentFocus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD1
2, 3CompletedTreatmentLiver Iron Overload1
2, 3Unknown StatusTreatmentBeta-Thalassemia Major / Iron Hemosiderosis / Sickle Cell Disorders1
3Active Not RecruitingOtherChronic Iron Overload1
3CompletedTreatmentAgnogenic Myeloid Metaplasia / Diamond Blackfan Anemia / Sickle Cell Disorders / Thalassaemic disorders1
3CompletedTreatmentBeta-Thalassemia1
3CompletedTreatmentBeta-Thalassemia / Hemosiderosis1
3CompletedTreatmentChronic Iron Overload1
3CompletedTreatmentHemosiderosis / Myelodysplastic Syndromes1
3CompletedTreatmentPorphyria Cutanea Tarda1
3CompletedTreatmentTransfusion-dependent Iron Overload1
3CompletedTreatmentTransfusional Iron Overload in β-thalassemia1
3TerminatedTreatmentSickle Cell Disorders / Transfusion Hemochromatosis / Transfusion Hemosiderosis1
4Active Not RecruitingTreatmentNon-transfusion Dependent Thalassemia1
4CompletedNot AvailableAnemias1
4CompletedTreatmentAplastic Anaemia (AA)1
4CompletedTreatmentAcute iron intoxication / Beta-Thalassemia Major / Hemosiderosis / Rare Anemia1
4CompletedTreatmentBeta-Thalassemia / Myelodysplastic Syndromes1
4CompletedTreatmentCongenital Hypoplastic Anemia / Haemoglobinopathies congenital / MPD Syndrome / Myelodysplastic Syndromes / Other Inherited or Acquired Anaemia / Other Inherited or Acquired Anaemia (e.g. MPD, Diamond-blackfan Anaemia and Other Rare Anaemias) / Other Rare Anaemias / Transfusional Iron Overload1
4CompletedTreatmentIron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major1
4CompletedTreatmentMyelodysplastic Syndrome1
4CompletedTreatmentMyelodysplastic Syndromes / Transfusion Dependent Iron Overload1
4CompletedTreatmentMyelodysplastic Syndrome / Thalassaemic disorders1
4CompletedTreatmentSickle Cell Disorders / Thalassemia Major (TM) / Transfusion-dependent Hemachromatosis1
4CompletedTreatmentAcute iron intoxication / Thalassaemic disorders1
4CompletedTreatmentTransfusional Hemosiderosis1
4CompletedTreatmentAcute iron intoxication2
4RecruitingTreatmentIron Over Load1
4TerminatedTreatmentMyelodysplastic Syndrome / Transfusional Iron Overload1
4WithdrawnSupportive CareThalassemia (Transfusion Delendent)1
4WithdrawnTreatmentΒ-thalassemia Major1
Not AvailableCompletedNot AvailableAcute iron intoxication / Thalassaemic disorders1
Not AvailableCompletedNot AvailableTransfusional Hemosiderosis1
Not AvailableCompletedBasic ScienceAnemias / Systemic Inflammatory Process1
Not AvailableCompletedTreatmentBeta-Thalassemia Major1
Not AvailableCompletedTreatmentAcute iron intoxication / Thalassaemic disorders / Transfusion Related Complications1
Not AvailableRecruitingNot AvailableMyelodysplastic Syndromes / Myeloid Leukemias1
Not AvailableRecruitingTreatmentAL-Hijama in Thalassmia Major1
Not AvailableRecruitingTreatmentAcute iron intoxication / Beta-Thalassemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Novartis AG
Dosage forms
FormRouteStrength
Tablet, film coatedOral180 mg
Tablet, film coatedOral360 mg
Tablet, film coatedOral90 mg
Tablet, for suspensionOral125 mg
Tablet, for suspensionOral125 mg/1
Tablet, for suspensionOral250 mg/1
Tablet, for suspensionOral250 mg
Tablet, for suspensionOral500 mg/1
Tablet, for suspensionOral500 mg
GranuleOral180 mg/1
GranuleOral360 mg/1
GranuleOral90 mg/1
TabletOral180 mg
TabletOral360 mg
TabletOral90 mg
Tablet, film coatedOral180 mg/1
Tablet, film coatedOral360 mg/1
Tablet, film coatedOral90 mg/1
Prices
Unit descriptionCostUnit
Exjade 500 mg tablet78.61USD tablet
Exjade 250 mg tablet39.3USD tablet
Exjade 125 mg tablet19.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2255951No2006-10-102017-06-24Canada
US6596750No1997-06-242017-06-24Us
US6465504No1999-04-052019-04-05Us
US9283209No2014-11-212034-11-21Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)116-117 °CNot Available
water solubility0.038 mg/mL at 37 °CYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.52HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0343 mg/mLALOGPS
logP4.01ALOGPS
logP4.74ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.55ChemAxon
pKa (Strongest Basic)0.19ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area108.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity125.32 m3·mol-1ChemAxon
Polarizability38.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.993
Blood Brain Barrier+0.8508
Caco-2 permeable+0.5089
P-glycoprotein substrateNon-substrate0.7808
P-glycoprotein inhibitor INon-inhibitor0.894
P-glycoprotein inhibitor IINon-inhibitor0.8431
Renal organic cation transporterNon-inhibitor0.8708
CYP450 2C9 substrateNon-substrate0.7212
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateNon-substrate0.6466
CYP450 1A2 substrateNon-inhibitor0.5802
CYP450 2C9 inhibitorNon-inhibitor0.7105
CYP450 2D6 inhibitorNon-inhibitor0.8221
CYP450 2C19 inhibitorNon-inhibitor0.5918
CYP450 3A4 inhibitorNon-inhibitor0.8179
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5717
Ames testNon AMES toxic0.6607
CarcinogenicityNon-carcinogens0.8519
BiodegradationNot ready biodegradable0.9524
Rat acute toxicity2.1119 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9684
hERG inhibition (predictor II)Non-inhibitor0.9072
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00fr-0009000000-e67e7fa4d17d7f182c35
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0109000000-f5f73c7f47b72dfe17b4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0v0r-0964000000-dc562f553f7e4c323be0
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0gb9-0940000000-b177b6270b3dbb4ef645
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0910000000-bbc4de8399359b50ab8d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0900000000-639f8a3ca67f3974334e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0009000000-975b5b37a916fce72ae0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0009000000-bb3998f3d2229ff0647e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0119000000-e52c7bac508e519d7425
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0awc-2920000000-f025e2ec3e1b9ab199ab
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-067i-4910000000-7092f8c0bcfae9c71d91
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-0119000000-080e3290dbc4b90d8e2d

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenyl-1,2,4-triazoles. These are organic compounds containing a 1,2,4-triazole substituted by a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Triazoles
Direct Parent
Phenyl-1,2,4-triazoles
Alternative Parents
Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds
show 3 more
Substituents
Phenyl-1,2,4-triazole / Benzoic acid or derivatives / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, phenols, benzoic acids, triazoles (CHEBI:49005)

Targets

1. Iron
Kind
Small molecule
Organism
Human
Pharmacological action
Yes
Actions
Chelator
References
  1. Wang T, Gao C, Chen BA: [Deferasirox--a new oral iron chelator--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1359-64. [PubMed:21129294]
  2. Ibrahim AS, Spellberg B, Edwards J Jr: Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008 Dec;21(6):620-5. doi: 10.1097/QCO.0b013e3283165fd1. [PubMed:18978530]
  3. Devanur LD, Evans RW, Evans PJ, Hider RC: Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy. Biochem J. 2008 Jan 15;409(2):439-47. [PubMed:17919118]
  4. Lebitasy M, Ampe E, Hecq JD, Karmani L, Nick H, Galanti L: Ability of deferasirox to bind iron during measurement of iron. Clin Chem Lab Med. 2010 Mar;48(3):427-9. doi: 10.1515/CCLM.2010.080. [PubMed:20170398]
  5. Yang LP, Keam SJ, Keating GM: Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. [PubMed:17927285]
  6. Choudhry VP, Naithani R: Current status of iron overload and chelation with deferasirox. Indian J Pediatr. 2007 Aug;74(8):759-64. [PubMed:17785900]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Skerjanec A, Wang J, Maren K, Rojkjaer L: Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):205-13. doi: 10.1177/0091270009340418. Epub 2009 Nov 25. [PubMed:19940232]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Allegra S, De Francia S, Cusato J, Arduino A, Massano D, Longo F, Piga A, D'Avolio A: Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554. doi: 10.2217/pgs-2016-0176. Epub 2017 Mar 27. [PubMed:28346059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Allegra S, De Francia S, Cusato J, Arduino A, Massano D, Longo F, Piga A, D'Avolio A: Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554. doi: 10.2217/pgs-2016-0176. Epub 2017 Mar 27. [PubMed:28346059]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Nakajima M, Yamanaka H, Fujiwara R, Katoh M, Yokoi T: Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. Drug Metab Dispos. 2007 Sep;35(9):1679-86. doi: 10.1124/dmd.107.015909. Epub 2007 Jun 18. [PubMed:17576806]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]

Drug created on August 29, 2007 13:21 / Updated on September 25, 2018 17:45